HOME > BUSINESS
BUSINESS
- Different Reactions from Industry Following Announcement of Stricter Requirements on Sales of Epadel OTC
January 15, 2013
- Takeda Launches Hyperlipidemia Treatment Lotriga
January 11, 2013
- Eisai Ties Up with Epizyme, RMS to Develop a Companion Diagnostic
January 11, 2013
- Seiichiro Matsumura Serves as New President of Alcon Japan
January 11, 2013
- Nichi-Iko Voluntarily Recalls Picillibacta IV Inj. 1.5 g
January 11, 2013
- Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
- Janssen Resumes Supply of Doxil
January 10, 2013
- Daiichi Sankyo to Jointly Develop Autoimmune Disease Therapy with Amplimmune
January 10, 2013
- Top Officials of Major Drug Makers Express Concerns Mixed with Some Understanding About New Pricing Rule for Long-Listed Drugs
January 10, 2013
- BI, Eli Lilly Plan to Submit SGLT-2 Inhibitor Empagliflozin for Approval in Japan, US, and Europe in 2013
January 10, 2013
- Novartis Launches Respiratory Infection Treatment Tobi
January 10, 2013
- Chugai Licenses Novel Anticancer Agent FF284 to Debiopharm of Switzerland
January 10, 2013
- Pharmaceutical Firms’ Leaders Hopeful of New Products and Determined to Build Stronger Business Foundations
January 9, 2013
- AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
- Sanofi Transfers Marketing Rights from Genzyme for Fludara
January 9, 2013
- Ajinomoto Pharmaceuticals Launches Atelec in Vietnam
January 9, 2013
- Novartis Pharma and Eisai Terminate Copromotion Agreement for COPD Therapies
January 9, 2013
- Bayer Yakuhin Files Eylea for Macular Edema Associated with CRVO
January 9, 2013
- Japan Should Invest More in Whole Genome Sequencing and Interpretation of Cancer-related Genomic Abnormalities: Dr Nakagawa of RIKEN
January 9, 2013
- BONAC Offers Solutions to Overcome Difficulties Faced in Development of Nucleic Acid Medicines: Managing Director Mizutani
January 9, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…